PubRank

T Schacker

Author PubWeight™ 26.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000 6.59
2 Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997 5.72
3 The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A 1997 2.24
4 Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol 1997 2.16
5 Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001 1.58
6 Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000 1.55
7 Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998 1.50
8 A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997 1.10
9 The relationship between tumor necrosis factor and human immunodeficiency virus gene expression in lymphoid tissue. J Virol 1997 0.95
10 Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol 1997 0.93
11 Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. J Infect Dis 1994 0.91
12 HSV-2 and HIV: consequences of an endemic opportunistic infection. STEP Perspect 1997 0.82
13 Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrob Agents Chemother 1993 0.76
14 Primary HIV infection. STEP Perspect 1996 0.75
15 Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection. J Med Virol 1993 0.75
16 Lack of detection of HSV DNA in PBMCs and lymph nodes of HIV-infected persons. J Med Virol 1996 0.75